Development of an auto-injector to enhance use of leukine as post-exposure prophylactic and treatment for warfighter radiation injuries in a limited resource environment
Active Other Transaction Agreement Awarded Last action
- Contract number
- W911SR269A021
- Awardee
-
Partner Therapeutics, Inc. UEI J33MSDBJZMC6
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $14,098,498
Award facts
- Contract value 29% obligated
-
- $14,098,498.19 Current, with exercised options
- $47,992,151.00 Potential, with all options
- Completion date 6% complete
- Current and potential, with all options
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
- Place of performance
- Lexington, MA 02421, USA
Award details come from SAM.gov/FPDS.
About this award
The Joint Program Executive Office Chemical and Biological Defense awarded an Other Transaction Agreement to Partner Therapeutics, Inc. on July 1, 2026, for development of an auto-injector to enhance use of Leukine as post-exposure prophylactic and treatment for warfighter radiation injuries in a limited resource environment, with a ceiling value of $47,992,151.
Work is performed in Lexington, Massachusetts, with an ultimate completion date of September 30, 2031. The agreement sits outside the FAR as an OTA, reflecting the Department of Defense's authority to pursue prototype and research-and-development efforts through alternative transaction mechanisms.
Partner Therapeutics specializes in therapeutics and medical countermeasures, with particular depth in sargramostim (Leukine) supply and related immunological biomarker development. The company's federal portfolio is concentrated among four defense and civilian health agencies, with prior work including a $22.3 million DoD OTA IDIQ awarded in January 2022 under Project Kickoff to advance FDA approval for Leukine in sulfur mustard injury treatment and a $13.7 million HHS ASPR definitive contract from September 2024 for advanced development of Leukine and biomarkers predictive of sepsis.
Quick answers
Who was awarded contract W911SR269A021?
W911SR269A021 was awarded to Partner Therapeutics, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on July 1, 2026.
How much is contract W911SR269A021 worth?
The government has obligated $14,098,498 on W911SR269A021. Its potential value, with all options, is $47,992,151.
Which agency awarded contract W911SR269A021?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR269A021, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911SR269A021 competed?
The extent of competition for W911SR269A021 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award